4 citations
,
August 2021 in “Biomedicine & Pharmacotherapy” This review summarizes the association between 5-alpha reductase inhibitors and depression, discussing potential mechanisms such as neuroactive steroid alterations and neuroinflammation, but reports no new clinical results.
1 citations
,
July 2021 in “DOAJ (DOAJ: Directory of Open Access Journals)”
2 citations
,
April 2021 in “Canadian Journal of Urology” This review summarizes existing studies on 5-alpha reductase inhibitors, noting their effectiveness in reducing prostate volume and cancer risk but highlighting an increased risk of higher grade prostate cancer.
41 citations
,
February 2021 in “Cureus” This study found that in males with mild COVID-19, treatment with dutasteride, along with standard therapy, may reduce viral shedding and inflammation compared to placebo.
49 citations
,
January 2021 in “Journal of The European Academy of Dermatology and Venereology” Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.
139 citations
,
December 2020 in “Cell Stem Cell” Male hormones affect COVID-19 severity and certain drugs targeting these hormones could help reduce the risk.
119 citations
,
May 2020 in “Journal of The American Academy of Dermatology” This study observed a high prevalence of androgenetic alopecia in patients hospitalized with severe COVID-19, with 79% of men and 42% of women affected, suggesting a potential link between androgen sensitivity and COVID-19 severity.
19 citations
,
April 2020 in “Dermatologic Therapy” This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.
47 citations
,
April 2020 in “Dermatologic Therapy” This letter discusses the potential connection between androgenetic alopecia and COVID-19, suggesting a possible new therapy, but it reports no new results.
15 citations
,
March 2020 in “Anais Brasileiros De Dermatologia” This review discusses post-finasteride syndrome, characterized by persistent symptoms despite discontinuation, and concludes that its existence cannot be confirmed; individualized assessment is advisable for those with a history of depression, sexual dysfunction, or infertility.
11 citations
,
August 2019 in “BMJ” This article reviews ongoing concerns about the safety of 5α-reductase inhibitors like finasteride, highlighting the lack of long-term data on persistent depression and sexual side effects after drug discontinuation; no new clinical results are reported.
4 citations
,
October 2018 in “International Braz J Urol” This study found no positive association between the use of 5α-reductase inhibitors and the risk of male breast cancer.
23 citations
,
April 2018 in “PubMed” This review finds preliminary evidence suggesting that topical finasteride may significantly reduce hair loss and increase hair counts in treating androgenetic alopecia, with a promising safety profile.
15 citations
,
January 2018 in “Acta dermato-venereologica” This meta-analysis found that treating male androgenetic alopecia with 5α-reductase inhibitors increases the risk of sexual dysfunction, with a statistically significant risk for finasteride but not for dutasteride.
18 citations
,
June 2017 in “Journal of the neurological sciences” In this study, the use of 5 alpha reductase inhibitors was associated with an increased risk of dementia during the first two years of treatment, but the risk was not significant with longer exposure.
153 citations
,
March 2017 in “Endocrine” This review examines recent advances in understanding the pathophysiology and molecular mechanisms of androgenetic alopecia, highlighting two major genetic risk loci, but does not report new clinical findings.
21 citations
,
January 2017 in “Dermatology Online Journal” This review discusses the sexual side effects of finasteride and dutasteride, two 5-α-reductase inhibitors, and reports no new clinical findings while calling for further research into dosage differences.
12 citations
,
December 2016 in “PubMed” This review discusses causes, diagnostic guidelines, and management strategies for hirsutism, highlighting the need for appropriate evaluations and treatment considerations in different patient populations, but reports no new clinical results.
57 citations
,
July 2016 in “The Journal of Sexual Medicine” This study concluded that 5α-reductase inhibitors were linked to increased sexual dysfunction in men with benign prostatic hyperplasia, but not in men with androgenetic alopecia.
15 citations
,
October 2014 in “Hormone Molecular Biology and Clinical Investigation” This report advances the hypothesis that finasteride and dutasteride inhibit 5α-reductase activities, potentially altering steroid metabolism and increasing the risk of insulin resistance, diabetes, and vascular disease.
93 citations
,
September 2014 in “Diabetes” This study found that male 5αR1 knockout mice and obese Zucker rats treated with finasteride showed increased insulin resistance and hepatic steatosis, potentially implicating 5α-reductase activity in metabolic liver disease development.
3 citations
,
May 2014 in “Urologia Journal” This review discusses how 5α-reductase inhibitors affect PSA levels in benign prostatic hyperplasia treatment and their role in prostate cancer screening, but reports no new clinical findings.
32 citations
,
February 2014 in “Psychopharmacology” This study found that dutasteride pretreatment reduced certain sedative effects of alcohol and may decrease drinking behavior in adult men, likely by impacting neuroactive steroid levels.
35 citations
,
April 2013 in “Sexual medicine reviews” This review found that 5α-reductase inhibitors are associated with slightly increased rates of sexual dysfunction, gynecomastia, and mood disorders, but the true significance and persistence of these effects remain unclear.
44 citations
,
October 2010 in “BJUI” This study found that 5‐α‐reductase inhibitors reduce the risk of being diagnosed with prostate cancer in men who undergo regular screening, but increase the risk of sexual and erectile dysfunction.
41 citations
,
April 2010 in “Gender Medicine” This review discusses the causes, clinical features, diagnostic approach, and treatment options for hirsutism in women, but reports no new findings.
1707 citations
,
December 2003 in “The New England Journal of Medicine” Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.
90 citations
,
January 2003 in “The Journal of Urology” This study found that finasteride significantly reduced VEGF expression and microvessel density in prostatic suburethral tissue, suggesting a mechanism for decreased bleeding in patients with benign prostatic hyperplasia.
109 citations
,
April 2000 in “European Urology” In this study, significantly fewer men treated with finasteride for moderate to severe BPH symptoms experienced acute urinary retention or required subsequent BPH-related surgery compared to placebo-treated patients.
1054 citations
,
February 1998 in “The New England Journal of Medicine” In this study, men with benign prostatic hyperplasia who took finasteride for four years experienced reduced urinary symptoms, fewer surgeries, less acute urinary retention, increased urinary flow rates, and decreased prostate volume.